治疗方式对分子分型WHO II级弥漫性胶质瘤无进展生存与总生存的影响:系统综述
该系统综述基于2016年WHO中枢神经系统肿瘤分类的分子分型,汇总比较了WHO II级弥漫性胶质瘤不同分子亚型在接受治疗背景下的无进展生存(PFS)与总生存(OS)。结果显示星形细胞瘤野生型WHO II级的OS显著短于突变型,少突胶质细胞瘤WHO II级的PFS显著优于星形细胞瘤突变型。
要点
- 星形细胞瘤野生型WHO II级OS中位32.2个月,显著短于突变型115.2个月(P=0.0002)。
- 少突胶质细胞瘤WHO II级OS中位163.7个月,与两型星形细胞瘤比较无显著差异。
- 三种分子亚型间PFS差异显著(P=0.015),少突胶质细胞瘤PFS优于星形细胞瘤突变型。
核心结论
- 星形细胞瘤野生型WHO II级的OS显著短于星形细胞瘤突变型WHO II级。
- 少突胶质细胞瘤WHO II级的OS与星形细胞瘤野生型及突变型比较均无显著差异。
- 三种分子亚型间PFS存在统计学显著差异,少突胶质细胞瘤WHO II级的PFS显著优于星形细胞瘤突变型WHO II级。
研究设计与样本
- 遵循PRISMA指南与Cochrane系统综述干预手册开展的系统综述。
- 检索MEDLINE、Embase和CENTRAL数据库。
- 纳入对象为2016年WHO分类下按分子亚型划分的WHO II级弥漫性星形细胞与少突胶质细胞肿瘤患者。
主要发现
- OS的25%、50%、75%分位及95%CI分别为:星形细胞瘤野生型WHO II级22.8、32.2、40.7个月及21.6-61.2个月。
- OS的25%、50%、75%分位及95%CI分别为:星形细胞瘤突变型WHO II级69.85、115.2、128.4个月及55.4-164.0个月。
- OS的25%、50%、75%分位及95%CI分别为:少突胶质细胞瘤WHO II级106.3、163.7、213.3个月及67.3-235.4个月,P=0.0002。
- PFS的25%、50%、75%分位及95%CI分别为:星形细胞瘤野生型WHO II级6.90、17.45、19.57个月及3.00-23.69个月。
- PFS的25%、50%、75%分位及95%CI分别为:星形细胞瘤突变型WHO II级37.20、43.20、55.63个月及35.7-60.0个月;少突胶质细胞瘤WHO II级47.42、59.2、88.28个月及46.3-91.2个月,P=0.015。
临床怎么用
- 分子分型可为WHO II级弥漫性胶质瘤患者提供预后分层信息。
- 生存差异有助于结合分子标志物理解治疗推荐并辅助未来临床试验设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: With the 2016 update of the World Health Organization (WHO) Classification of Tumors of the Central Nervous System incorporating molecular subtyping to histology, WHO grade II diffuse astrocytic and oligodendroglial tumors are subcategorized by distinct molecular markers. There are no reported systematic reviews quantifying differences in progression-free survival (PFS) and overall survival (OS) on the basis of molecular subtypes of WHO grade II diffuse gliomas, against the background of administered treatments. METHODS: Using the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines and the Cochrane Handbook of Systemic Reviews of Interventions, we conducted a systematic review through MEDLINE, Embase, and CENTRAL (Cochrane Central Register of Controlled Trails). RESULTS: For OS, the first quartile (25%), median (50%), third quartile (75%), and 95% confidence interval, respectively, were identified (in months): astrocytoma-wild-type WHO II (A-wt II): 22.8, 32.2, 40.7, and 21.6-61.2; astrocytoma-mutant WHO II (A-mt II): 69.85, 115.2, 128.4, and 55.4-164.0; oligodendroglioma WHO II (OD-II): 106.3, 163.7, 213.3, and 67.3-235.4 (P value = 0.0002). For PFS, the 25th, 50th, and 75th percentiles, and 95% confidence interval, respectively, are as follows (in months): A-wt II: 6.90, 17.45, 19.57, and 3.00-23.69; A-mt II: 37.20, 43.20, 55.63, and 35.7-60.0; OD-II: 47.42, 59.2, 88.28, and 46.3-91.2 (P value = 0.015). CONCLUSIONS: This seems to be the first systematic review of OS and PFS in patients with WHO grade II low-grade gliomas (LGGs), against treatment modalities, in molecularly stratified subsets introduced by the WHO 2016 classification of central nervous system tumors. Overall, A-wt II was confirmed to have a significantly shorter OS than did A-mt II; no significant difference was found between OS of OD-II with A-wt II and A-mt II. In addition, all 3 molecular subtypes were found to have statistically significant differences between PFS, with OD-II having a statistically better PFS than A-mt II. These data can provide valuable prognostic insight to patients and clinicians. In addition, assessing survival differences enhances understanding of treatment recommendations against molecular markers and may facilitate future clinical trial design.
引用
- Ghaffari-Rafi A, Samandouras G. Effect of Treatment Modalities on Progression-Free Survival and Overall Survival in Molecularly Subtyped World Health Organization Grade II Diffuse Gliomas: A Systematic Review. World Neurosurg. 2019. PMID: 31473344. doi:10.1016/j.wneu.2019.08.111
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。